Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
17. Juni 2019 07:30 ET
|
Voyager Therapeutics, Inc.
Gains worldwide rights to VY-HTT01 for Huntington’s disease Resources to be reallocated to VY-HTT01 and other programs; intends to seek a partner for the SOD1 ALS program CAMBRIDGE, Mass., June 17,...
Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
29. April 2019 07:04 ET
|
Voyager Therapeutics, Inc.
Voyager’s vectorized antibody program directed against tau demonstrates antibody distribution and expression levels in specific cell types that further facilitate studies with a vectorized antibody in...